Final Technical Consortium Meeting - BMGF, Seattle, USA

13 February 2015
Rapid, disposable diagnostic malaria test  A village malaria worker takes a blood sample from 12 year old Yim Pros in Phnom Dambang Village in Cambodia

Consortium groups from across disease areas to present final results to BMGF in Seattle, USA

16 - 20 February 2015

Diagnostics Consortium Final Technical Meeting of all modelling teams to be held in conjunction with PST teams and stakeholders at the Bill & Melinda Gates Foundation, Seattle, USA.

Four consecutive face to face meetings are being coordinated by the Consortium Secretariat to allow teams to showcase their final modelling results to the Consortium's programme officers from the Bill and Melinda Gates Foundation

The main purpose of these meetings is for partners to share final results of the project related studies with the Bill and Melinda Gates Foundation staff from individual PST and cross cutting teams, as the activities come to a close. The core objectives include sharing results and data, to coordinate next steps to translate results into publications, continued interactions with key stakeholders, plans for dissemination and translating research into policy and the transition of the Consortium’s research priorities into the related Foundation funded Consortia.

Members of the Consortium malaria groups span across the EU and SE Asia, including Imperial College London, Swiss TPH, Radboud University Nijmegen, Netherlands, Mahidol Oxford Tropical Research Unit, Thailand and London School of Hygiene & Tropical Medicine, UK. Their work has focused on infectivity and diagnostics, specifically how individuals contribute to onwards transmission and how sensitive diagnostic tests need to be in different usage scenarios, what could a higher sensitivity diagnostic detect and what impact could such increased sensitivity have on malaria elimination programmes?

The Visceral Leishmaniasis (VL) work carried out by the University of Warwick and the Liverpool School of Tropical Medicine, in conjunction with Erasmus MC and PATH, has focused on the relative roles of sub-clinical infection, clinical VL and PKDL in maintaining the transmission cycle. They will also present an update on the desired product profile for a field-based diagnostic to ensure the success of IRS and different testing and treatment strategies to reduce and interrupt transmission of VL. This final meeting will also provide an opportunity to discuss the work already underway relating to the PATH partner project, 'Tools for the Endgame'.

The HIV groups from both the University of Washington, USA and Penn State, USA will present findings from their systematic review and metanalysis incorporating more than 1800 publications on HIV testing strategies and cost, the ‘gateway’ to delivery and uptake of effective HIV care and prevention, together with an analysis of HIV incidence estimations and the target product profiles for HIV incidence assay development.

The Pneumo team from Imperial College London have been analysing the impact of improved prognostics on pneumonia incidence and deaths in resource-poor settings.